+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Duvelisib for Relapsed CLL/SLL Market by Treatment Regimen (Combination Therapy, Monotherapy), Line Of Therapy (Second-Line, Third-Line And Above), Distribution Channel, End User, Patient Age Group - Global Forecast 2025-2030- Product Image
Duvelisib for Relapsed CLL/SLL Market by Treatment Regimen (Combination Therapy, Monotherapy), Line Of Therapy (Second-Line, Third-Line And Above), Distribution Channel, End User, Patient Age Group - Global Forecast 2025-2030- Product Image
Sale

Duvelisib for Relapsed CLL/SLL Market by Treatment Regimen (Combination Therapy, Monotherapy), Line Of Therapy (Second-Line, Third-Line And Above), Distribution Channel, End User, Patient Age Group - Global Forecast 2025-2030

  • PDF Icon

    Report

  • 197 Pages
  • August 2025
  • Region: Global
  • 360iResearch™
  • ID: 6084545
UP TO OFF until Jan 01st 2026
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

Duvelisib is transforming the treatment landscape for relapsed or refractory chronic lymphocytic leukaemia (CLL) and small lymphocytic lymphoma (SLL) by addressing persistent unmet clinical needs. Senior decision-makers seeking to future-proof their strategies should evaluate this market’s fast-evolving combination therapies, supply chain shifts, competitive dynamics, and the operational impact of new regulatory frameworks.

Market Snapshot: Duvelisib in Relapsed CLL/SLL

The market for duvelisib in relapsed or refractory CLL and SLL is witnessing substantial growth, fuelled by the increasing need for targeted therapies and continued innovation in hematologic oncology. With rising incidences of CLL/SLL and the prevalence of therapeutic resistance in later lines of treatment, demand for dual-action PI3K inhibitors is expanding globally. The market’s momentum is accelerated by regulatory approvals, broadened clinical uptake across developed healthcare infrastructures, and strategic collaborations between biopharmaceutical leaders. Duvelisib’s regulatory endorsements and demonstrated clinical effectiveness are key drivers that attract the attention of both healthcare providers and payers, underpinning the market’s robust compound annual growth rate (CAGR) and revenue expansion. Primary keyword: duvelisib, Secondary keywords: relapsed CLL, PI3K inhibitor, hematologic malignancies

Scope & Segmentation

This report provides comprehensive coverage by segmenting the duvelisib market based on multiple, decision-critical criteria:

  • Treatment Regimen: Combination therapy, monotherapy
  • Line of Therapy: Second-line, third-line and above
  • Distribution Channel: Hospital pharmacy, online pharmacy, retail pharmacy, specialty pharmacy
  • End User: Homecare service, hospital, specialty clinic
  • Patient Age Group: Adult, geriatric
  • Region: Americas (including United States, Canada, Mexico, Brazil, Argentina), Europe/Middle East/Africa (including United Kingdom, Germany, France, Russia, Italy, Spain, United Arab Emirates, Saudi Arabia, South Africa, Denmark, Netherlands, Qatar, Finland, Sweden, Nigeria, Egypt, Turkey, Israel, Norway, Poland, Switzerland), and Asia-Pacific (including China, India, Japan, Australia, South Korea, Indonesia, Thailand, Philippines, Malaysia, Singapore, Vietnam, Taiwan)
  • Leading Companies: AbbVie Inc., Johnson & Johnson, AstraZeneca plc, Roche Holding AG, BeiGene, Ltd., Gilead Sciences, Inc., Verastem Oncology, Inc.

The report also delves into supply chain links, regulatory environments, digital health integration, and competitive strategies that influence clinical adoption, patient access, and reimbursement.

Key Takeaways for Decision-Makers

  • Duvelisib’s dual inhibition mechanism breaks traditional therapeutic resistance and provides a targeted option for patients who have relapsed after standard interventions.
  • Combination regimens integrating duvelisib with other targeted agents are driving improved response rates, prompting prescribers to reevaluate sequencing and toxicity management for relapsed CLL.
  • Strategic partnerships and co-development programs are accelerating the integration of duvelisib with emerging immunotherapies, enhancing clinical and commercial viability across global markets.
  • Transitioning from single-isoform PI3K inhibitor approaches to dual-action agents marks a significant paradigm shift, addressing feedback loops implicated in hematologic malignancies’ resistance.
  • Segmentation by age group and care setting is increasingly relevant, as adult and geriatric patients present distinct tolerability and support requirements, influencing distribution and engagement approaches.
  • Outcome-based agreements, expanded use of real-world data, and digital monitoring tools are rapidly influencing market access negotiations and long-term therapy management.

Tariff Impact: Navigating 2025 U.S. Policy Shifts

Recent U.S. tariff adjustments affecting pharmaceutical raw materials in 2025 are reshaping pricing and supply strategies across the duvelisib ecosystem. As manufacturing costs shift, stakeholders from manufacturers to payers re-examine procurement, reimbursement, and formulary placement. This climate demands agile scenario planning, diversified sourcing, and robust engagement with managed care organizations to protect patient access and long-term pricing stability.

Methodology & Data Sources

Our analysis integrates secondary research from peer-reviewed journals, regulatory filings, and clinical trial registries with primary interviews from oncologists, payers, pharmacists, and advocacy leaders in core markets. Data triangulation, thematic mapping, and peer review safeguard the integrity and applicability of insights shared in this executive summary.

Why This Report Matters

  • Enables precise benchmarking of duvelisib adoption strategies in relapsed CLL/SLL by segment, geography, and care setting.
  • Arms senior leaders with actionable recommendations for navigating regulatory complexity, tariff fluctuations, and competitive change.
  • Supports informed resource allocation for operationalizing patient-centric, data-driven market entry and expansion plans.

Conclusion

Duvelisib’s dual-action mechanism and solid clinical relevance position it at the forefront of relapsed CLL/SLL treatment. Strategic alignment with care segments and supply chain adaptations will be essential for capturing growth and ensuring meaningful outcomes in this evolving market.



This product will be delivered within 1-3 business days.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Sizing & Forecasting
5. Market Dynamics
5.1. Impact of emerging PI3K inhibitor safety data on duvelisib prescribing patterns in relapsed CLL/SLL
5.2. Shifts in payer reimbursement policies for second-line duvelisib therapy in relapsed CLL/SLL patients
5.3. Real-world evidence comparing duvelisib combination regimens versus monotherapy in heavily pretreated CLL/SLL
5.4. Competitive landscape evolution with novel BTK and BCL-2 inhibitors challenging duvelisib adoption
5.5. Patient adherence and toxicity management strategies influencing duvelisib treatment outcomes in relapsed CLL/SLL
6. Market Insights
6.1. Porter’s Five Forces Analysis
6.2. PESTLE Analysis
7. Cumulative Impact of United States Tariffs 2025
8. Duvelisib for Relapsed CLL/SLL Market, by Treatment Regimen
8.1. Introduction
8.2. Combination Therapy
8.3. Monotherapy
9. Duvelisib for Relapsed CLL/SLL Market, by Line Of Therapy
9.1. Introduction
9.2. Second-Line
9.3. Third-Line And Above
10. Duvelisib for Relapsed CLL/SLL Market, by Distribution Channel
10.1. Introduction
10.2. Hospital Pharmacy
10.3. Online Pharmacy
10.4. Retail Pharmacy
10.5. Specialty Pharmacy
11. Duvelisib for Relapsed CLL/SLL Market, by End User
11.1. Introduction
11.2. Homecare Service
11.3. Hospital
11.4. Specialty Clinic
12. Duvelisib for Relapsed CLL/SLL Market, by Patient Age Group
12.1. Introduction
12.2. Adult
12.3. Geriatric
13. Americas Duvelisib for Relapsed CLL/SLL Market
13.1. Introduction
13.2. United States
13.3. Canada
13.4. Mexico
13.5. Brazil
13.6. Argentina
14. Europe, Middle East & Africa Duvelisib for Relapsed CLL/SLL Market
14.1. Introduction
14.2. United Kingdom
14.3. Germany
14.4. France
14.5. Russia
14.6. Italy
14.7. Spain
14.8. United Arab Emirates
14.9. Saudi Arabia
14.10. South Africa
14.11. Denmark
14.12. Netherlands
14.13. Qatar
14.14. Finland
14.15. Sweden
14.16. Nigeria
14.17. Egypt
14.18. Turkey
14.19. Israel
14.20. Norway
14.21. Poland
14.22. Switzerland
15. Asia-Pacific Duvelisib for Relapsed CLL/SLL Market
15.1. Introduction
15.2. China
15.3. India
15.4. Japan
15.5. Australia
15.6. South Korea
15.7. Indonesia
15.8. Thailand
15.9. Philippines
15.10. Malaysia
15.11. Singapore
15.12. Vietnam
15.13. Taiwan
16. Competitive Landscape
16.1. Market Share Analysis, 2024
16.2. FPNV Positioning Matrix, 2024
16.3. Competitive Analysis
16.3.1. AbbVie Inc.
16.3.2. Johnson & Johnson
16.3.3. AstraZeneca plc
16.3.4. Roche Holding AG
16.3.5. BeiGene, Ltd.
16.3.6. Gilead Sciences, Inc.
16.3.7. Verastem Oncology, Inc.
17. Research AI18. Research Statistics19. Research Contacts20. Research Articles21. Appendix
List of Figures
FIGURE 1. DUVELISIB FOR RELAPSED CLL/SLL MARKET RESEARCH PROCESS
FIGURE 2. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 3. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY REGION, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 4. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 5. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2030 (%)
FIGURE 6. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 7. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2030 (%)
FIGURE 8. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2030 (%)
FIGURE 10. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 11. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2024 VS 2030 (%)
FIGURE 12. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 13. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2030 (%)
FIGURE 14. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 16. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY STATE, 2024 VS 2030 (%)
FIGURE 18. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY STATE, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 20. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 21. ASIA-PACIFIC DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2030 (%)
FIGURE 22. ASIA-PACIFIC DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2030 (USD MILLION)
FIGURE 23. DUVELISIB FOR RELAPSED CLL/SLL MARKET SHARE, BY KEY PLAYER, 2024
FIGURE 24. DUVELISIB FOR RELAPSED CLL/SLL MARKET, FPNV POSITIONING MATRIX, 2024
FIGURE 25. DUVELISIB FOR RELAPSED CLL/SLL MARKET: RESEARCHAI
FIGURE 26. DUVELISIB FOR RELAPSED CLL/SLL MARKET: RESEARCHSTATISTICS
FIGURE 27. DUVELISIB FOR RELAPSED CLL/SLL MARKET: RESEARCHCONTACTS
FIGURE 28. DUVELISIB FOR RELAPSED CLL/SLL MARKET: RESEARCHARTICLES
List of Tables
TABLE 1. DUVELISIB FOR RELAPSED CLL/SLL MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
TABLE 3. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, 2018-2024 (USD MILLION)
TABLE 4. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, 2025-2030 (USD MILLION)
TABLE 5. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
TABLE 6. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY REGION, 2025-2030 (USD MILLION)
TABLE 7. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 8. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 9. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 10. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 11. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 12. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COMBINATION THERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 13. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY MONOTHERAPY, BY REGION, 2018-2024 (USD MILLION)
TABLE 14. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY MONOTHERAPY, BY REGION, 2025-2030 (USD MILLION)
TABLE 15. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 16. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 17. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY SECOND-LINE, BY REGION, 2018-2024 (USD MILLION)
TABLE 18. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY SECOND-LINE, BY REGION, 2025-2030 (USD MILLION)
TABLE 19. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY THIRD-LINE AND ABOVE, BY REGION, 2018-2024 (USD MILLION)
TABLE 20. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY THIRD-LINE AND ABOVE, BY REGION, 2025-2030 (USD MILLION)
TABLE 21. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 22. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 23. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 24. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 25. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 26. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY ONLINE PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 27. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 28. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 29. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2018-2024 (USD MILLION)
TABLE 30. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY SPECIALTY PHARMACY, BY REGION, 2025-2030 (USD MILLION)
TABLE 31. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 32. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 33. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY HOMECARE SERVICE, BY REGION, 2018-2024 (USD MILLION)
TABLE 34. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY HOMECARE SERVICE, BY REGION, 2025-2030 (USD MILLION)
TABLE 35. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2024 (USD MILLION)
TABLE 36. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY HOSPITAL, BY REGION, 2025-2030 (USD MILLION)
TABLE 37. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 38. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY SPECIALTY CLINIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 39. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 40. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 41. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY ADULT, BY REGION, 2018-2024 (USD MILLION)
TABLE 42. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY ADULT, BY REGION, 2025-2030 (USD MILLION)
TABLE 43. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY GERIATRIC, BY REGION, 2018-2024 (USD MILLION)
TABLE 44. GLOBAL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY GERIATRIC, BY REGION, 2025-2030 (USD MILLION)
TABLE 45. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 46. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 47. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 48. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 49. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 50. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 51. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 52. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 53. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 54. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 55. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 56. AMERICAS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 57. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 58. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 59. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 60. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 61. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 62. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 63. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 64. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 65. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 66. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 67. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY STATE, 2018-2024 (USD MILLION)
TABLE 68. UNITED STATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY STATE, 2025-2030 (USD MILLION)
TABLE 69. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 70. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 71. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 72. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 73. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 74. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 75. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 76. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 77. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 78. CANADA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 79. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 80. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 81. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 82. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 83. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 84. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 85. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 86. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 87. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 88. MEXICO DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 89. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 90. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 91. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 92. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 93. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 94. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 95. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 96. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 97. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 98. BRAZIL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 99. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 100. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 101. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 102. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 103. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 104. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 105. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 106. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 107. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 108. ARGENTINA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 109. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 110. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 111. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 112. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 113. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 114. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 115. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 116. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 117. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 118. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 119. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
TABLE 120. EUROPE, MIDDLE EAST & AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY COUNTRY, 2025-2030 (USD MILLION)
TABLE 121. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 122. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 123. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 124. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 125. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 126. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 127. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 128. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 129. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 130. UNITED KINGDOM DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 131. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 132. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 133. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 134. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 135. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 136. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 137. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 138. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 139. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 140. GERMANY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 141. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 142. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 143. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 144. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 145. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 146. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 147. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 148. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 149. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 150. FRANCE DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 151. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 152. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 153. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 154. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 155. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 156. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 157. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 158. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 159. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 160. RUSSIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 161. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 162. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 163. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 164. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 165. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 166. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 167. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 168. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 169. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 170. ITALY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 171. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 172. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 173. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 174. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 175. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 176. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 177. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 178. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 179. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 180. SPAIN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 181. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 182. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 187. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 188. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 189. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 190. UNITED ARAB EMIRATES DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 191. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 192. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 193. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 194. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 196. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 198. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 199. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 200. SAUDI ARABIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 202. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 204. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 205. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 206. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 207. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 208. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 209. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 210. SOUTH AFRICA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 211. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 212. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 213. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 214. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 215. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 216. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 217. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 218. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 219. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 220. DENMARK DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 221. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 222. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 223. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 224. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 225. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 226. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 227. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 228. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 229. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 230. NETHERLANDS DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 231. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 232. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 233. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 234. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 235. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 236. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 237. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 238. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 239. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 240. QATAR DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 241. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 242. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 243. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 244. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 245. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 246. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 247. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 248. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 249. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 250. FINLAND DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 251. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 252. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 253. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 254. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 255. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 256. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 257. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 258. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 259. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 260. SWEDEN DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 261. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 262. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 263. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 264. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 265. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 266. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 267. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 268. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 269. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 270. NIGERIA DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 271. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 272. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 273. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 274. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 275. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 276. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 277. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 278. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 279. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 280. EGYPT DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 281. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 282. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 283. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 284. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 285. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 286. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 287. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 288. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 289. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 290. TURKEY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 291. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 292. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2025-2030 (USD MILLION)
TABLE 293. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2018-2024 (USD MILLION)
TABLE 294. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY LINE OF THERAPY, 2025-2030 (USD MILLION)
TABLE 295. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2024 (USD MILLION)
TABLE 296. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY DISTRIBUTION CHANNEL, 2025-2030 (USD MILLION)
TABLE 297. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2018-2024 (USD MILLION)
TABLE 298. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY END USER, 2025-2030 (USD MILLION)
TABLE 299. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2018-2024 (USD MILLION)
TABLE 300. ISRAEL DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY PATIENT AGE GROUP, 2025-2030 (USD MILLION)
TABLE 301. NORWAY DUVELISIB FOR RELAPSED CLL/SLL MARKET SIZE, BY TREATMENT REGIMEN, 2018-2024 (USD MILLION)
TABLE 302. NORWAY DUV

Samples

Loading
LOADING...

Companies Mentioned

The companies profiled in this Duvelisib for Relapsed CLL/SLL market report include:
  • AbbVie Inc.
  • Johnson & Johnson
  • AstraZeneca plc
  • Roche Holding AG
  • BeiGene, Ltd.
  • Gilead Sciences, Inc.
  • Verastem Oncology, Inc.

Related Topics

Related Reports

Pharmaceuticals - Enterprise ICT - Product Image

Pharmaceuticals - Enterprise ICT

  • Report
  • 54 Pages
  • Global
From
Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028 - Product Image

Pharmaceuticals North America (NAFTA) Industry Guide 2019-2028

  • Report
  • 286 Pages
  • North America
From
Asia-Pacific Pharmaceutical Industry Outlook 2023 - Product Image

Asia-Pacific Pharmaceutical Industry Outlook 2023

  • Report
  • 77 Pages
  • Asia Pacific
From
Pharmaceutical Automation - Global Strategic Business Report - Product Image

Pharmaceutical Automation - Global Strategic Business Report

  • Report
  • 371 Pages
  • Global
From
Incontinence Medication Market by Incontinence Type (Functional, Mixed, Overflow), Treatment Type (Combination Therapies, Oral Drugs, Topical Agents), Distribution Channel, Route Of Administration, Age Group - Global Forecast 2025-2030 - Product Image

Incontinence Medication Market by Incontinence Type (Functional, Mixed, Overflow), Treatment Type (Combination Therapies, Oral Drugs, Topical Agents), Distribution Channel, Route Of Administration, Age Group - Global Forecast 2025-2030

  • Report
  • 183 Pages
  • Global
From
Copyright © 2002-2025 Research and Markets. All Rights Reserved.